HOUSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on October…
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD)…
Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a…
HOUSTON, TX, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader…
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to…
If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapysBLA submission…
TAMPA, FLORIDA / ACCESS Newswire / October 13, 2025 / Wellgistics Health, Inc. ("Wellgistics" or the "Company") (NASDAQ:WGRX), a leader…
Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17,…
EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST PHILADELPHIA, PENNSYLVANIA / ACCESS…
Findings suggest a subset of Major Depressive Disorder patients may respond preferentially to vasopressin V1b receptor antagonismMUNICH, Oct. 13, 2025…